Bupropion XL
Sponsors
GlaxoSmithKline, St. Luke's-Roosevelt Hospital Center, University Health Network, Toronto, University of California, Los Angeles, University of British Columbia
Conditions
Bipolar I DisorderCocaine DependenceDepressionDepressive Disorder, MajorDysthymic DisorderMajor DepressionMajor Depressive DisorderSubstance Abuse
Phase 2
Phase 3
Major Depressive Disorder In The Elderly
CompletedNCT00093288
Start: 2004-06-30End: 2005-10-31Target: 364Updated: 2013-09-02
Memory Functioning and Antidepressant Treatment
CompletedNCT00296933
Start: 2005-12-31Target: 60Updated: 2009-02-17
Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.
TerminatedNCT00958633
Start: 2010-11-30End: 2020-05-20Updated: 2025-05-15
Phase 4
Wellbutrin XL for Dysthymic Disorder
CompletedNCT00225251
Start: 2004-11-30End: 2008-06-30Updated: 2015-11-26
Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)
CompletedNCT00917059
Start: 2009-05-31End: 2012-05-31Updated: 2013-02-06
Connectivity Affecting the Antidepressant REsponse Study
CompletedNCT02332291
Start: 2015-04-30End: 2020-08-31Updated: 2021-09-21
Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits
CompletedNCT04352101
Start: 2020-09-23End: 2022-07-25Updated: 2023-12-29